ResMed Beheer
Beheer criteriumcontroles 4/4
De CEO ResMed is Mick Farrell, benoemd in Mar2013, heeft een ambtstermijn van 11.67 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 14.12M, bestaande uit 8.3% salaris en 91.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.31% van de aandelen van het bedrijf, ter waarde $ 111.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.8 jaar en 7 jaar.
Belangrijke informatie
Mick Farrell
Algemeen directeur
US$14.1m
Totale compensatie
| Percentage CEO-salaris | 8.3% |
| Dienstverband CEO | 11.7yrs |
| Eigendom CEO | 0.3% |
| Management gemiddelde ambtstermijn | 2.8yrs |
| Gemiddelde ambtstermijn bestuur | 7yrs |
Recente managementupdates
Recent updates
Shareholders May Not Be So Generous With ResMed Inc.'s (NYSE:RMD) CEO Compensation And Here's Why
Nov 13
We Think ResMed (NYSE:RMD) Can Manage Its Debt With Ease
Nov 01Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Oct 20ResMed Inc.'s (NYSE:RMD) Intrinsic Value Is Potentially 47% Above Its Share Price
Oct 08Why ResMed's Rally Is Just Getting Started
Sep 18ResMed Inc.'s (NYSE:RMD) Earnings Haven't Escaped The Attention Of Investors
Sep 13ResMed (NYSE:RMD) Is Increasing Its Dividend To $0.53
Aug 05Does ResMed (NYSE:RMD) Have A Healthy Balance Sheet?
Jul 29Returns On Capital Are A Standout For ResMed (NYSE:RMD)
Jul 15ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
Jul 03An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
Jul 02ResMed (NYSE:RMD) Seems To Use Debt Quite Sensibly
Apr 30Earnings Beat: ResMed Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Apr 30ResMed Inc.'s (NYSE:RMD) Popularity With Investors Is Clear
Apr 18With EPS Growth And More, ResMed (NYSE:RMD) Makes An Interesting Case
Mar 22Capital Investments At ResMed (NYSE:RMD) Point To A Promising Future
Mar 10An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 30% Undervalued
Feb 12Why ResMed Is One Of My Top Picks In 2024
Jan 22A First Look At ResMed
Jan 09ResMed Inc.'s (NYSE:RMD) Share Price Could Signal Some Risk
Dec 20Why You Should Care About ResMed's (NYSE:RMD) Strong Returns On Capital
Dec 06Shareholders May Find It Hard To Justify Increasing ResMed Inc.'s (NYSE:RMD) CEO Compensation For Now
Nov 10Are Investors Undervaluing ResMed Inc. (NYSE:RMD) By 41%?
Nov 01ResMed: Weight-Loss Drug Worries Provide Buying Opportunity
Oct 28ResMed: Stock Re-Rating To 20x Forward P/E Is A Buy Opportunity
Sep 12ResMed Has Become A Steal (Rating Upgrade)
Aug 10ResMed's (NYSE:RMD) Shareholders Will Receive A Bigger Dividend Than Last Year
Aug 07ResMed (NYSE:RMD) Has Some Way To Go To Become A Multi-Bagger
Jul 30Here's Why We Think ResMed (NYSE:RMD) Might Deserve Your Attention Today
Jul 16Compound Your Wealth With ResMed
Jul 04A Look At The Fair Value Of ResMed Inc. (NYSE:RMD)
Jul 02We Think ResMed (NYSE:RMD) Can Stay On Top Of Its Debt
May 26Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$1b |
| Jun 30 2024 | US$14m | US$1m | US$1b |
| Mar 31 2024 | n/a | n/a | US$958m |
| Dec 31 2023 | n/a | n/a | US$890m |
| Sep 30 2023 | n/a | n/a | US$907m |
| Jun 30 2023 | US$14m | US$1m | US$898m |
| Mar 31 2023 | n/a | n/a | US$863m |
| Dec 31 2022 | n/a | n/a | US$809m |
| Sep 30 2022 | n/a | n/a | US$786m |
| Jun 30 2022 | US$12m | US$1m | US$779m |
| Mar 31 2022 | n/a | n/a | US$779m |
| Dec 31 2021 | n/a | n/a | US$522m |
| Sep 30 2021 | n/a | n/a | US$500m |
| Jun 30 2021 | US$10m | US$1m | US$475m |
| Mar 31 2021 | n/a | n/a | US$457m |
| Dec 31 2020 | n/a | n/a | US$699m |
| Sep 30 2020 | n/a | n/a | US$680m |
| Jun 30 2020 | US$10m | US$1m | US$622m |
| Mar 31 2020 | n/a | n/a | US$513m |
| Dec 31 2019 | n/a | n/a | US$455m |
| Sep 30 2019 | n/a | n/a | US$419m |
| Jun 30 2019 | US$10m | US$967k | US$405m |
| Mar 31 2019 | n/a | n/a | US$446m |
| Dec 31 2018 | n/a | n/a | US$450m |
| Sep 30 2018 | n/a | n/a | US$335m |
| Jun 30 2018 | US$9m | US$934k | US$316m |
Compensatie versus markt: De totale vergoeding ($USD 14.12M ) Mick } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.73M ).
Compensatie versus inkomsten: De vergoeding van Mick is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Mick Farrell (52 yo)
11.7yrs
Tenure
US$14,120,829
Compensatie
Mr. Michael J. Farrell, also known as Mick, BE, SM, MBA, served as Director of Fullbay, Inc. since May 2023 until 2023. He serves as Member of Advisory Board at Green Sun Medical, LLC. He serves as the Chi...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 11.7yrs | US$14.12m | 0.31% $ 111.0m | |
| Founder | no data | US$719.69k | 0.056% $ 20.0m | |
| Chief Financial Officer | 18.8yrs | US$3.23m | 0.065% $ 22.9m | |
| Chief Legal Officer & Secretary | 1.3yrs | US$2.15m | 0.0064% $ 2.3m | |
| Chief Product Officer | 8.5yrs | US$3.60m | 0.013% $ 4.5m | |
| Chief Commercial Officer - SaaS | 2.8yrs | US$3.53m | 0.013% $ 4.7m | |
| Chief Information Officer | less than a year | geen gegevens | geen gegevens | |
| Chief Investor Relations Officer | 1.6yrs | geen gegevens | geen gegevens | |
| Chief Compliance Officer | 6.8yrs | geen gegevens | geen gegevens | |
| Chief Marketing Officer | less than a year | geen gegevens | geen gegevens | |
| Chief People Officer | 3.7yrs | geen gegevens | geen gegevens | |
| Special Advisor | less than a year | US$6.67m | 0% $ 0 |
2.8yrs
Gemiddelde duur
57yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van RMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| CEO & Chairman | 11.7yrs | US$14.12m | 0.31% $ 111.0m | |
| Founder | 35.4yrs | US$719.69k | 0.056% $ 20.0m | |
| Independent Director | 19.3yrs | US$348.72k | 0.010% $ 3.6m | |
| Lead Independent Director | 19.8yrs | US$381.22k | 0.014% $ 5.0m | |
| Independent Non-Executive Director | 5.5yrs | US$329.97k | 0.0046% $ 1.6m | |
| Independent Director | 6yrs | US$329.97k | 0.0060% $ 2.1m | |
| Independent Director | 11yrs | US$369.97k | 0.010% $ 3.6m | |
| Independent Director | 7yrs | US$334.97k | 0.0052% $ 1.8m | |
| Independent Director | less than a year | geen gegevens | geen gegevens | |
| Independent Director | 3yrs | US$329.97k | 0.0014% $ 503.3k | |
| Independent Director | 3yrs | US$329.97k | 0.0014% $ 503.3k |
7.0yrs
Gemiddelde duur
60yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van RMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).